FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COLUMN GROUP II, LP		 2. Issuer Name and Ticker or Trading Symbol

RAPT Therapeutics, Inc. [ RAPT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

1700 OWENS STREET, SUITE 500		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/18/2020
(Street)

SAN FRANCISCO, CA 94158
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $28.27 6/18/2020  J   22500     (1)6/17/2030 Common Stock 22500 $0.00 22500 I See Footnote (2)
Explanation of Responses:
(1) The option shall vest in a series of three successive equal annual installments over the three-year period measured from the date of grant, subject to the continuous service of Peter Svennilson as a director of the Issuer through each applicable vesting date.
(2) The option was granted to Peter Svennilson, a director of the Issuer who is a managing partner of The Column Group II GP, LP ("TCG II GP"), Ponoi Management, LLC ("Ponoi LLC") and Ponoi II Management, LLC ("Ponoi II LLC"), which are the general partners of The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and, together with TCG II LP and Ponoi LP, the "Funds"), respectively. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of Ponoi LLC and Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. Under the partnership agreements of the Funds, Mr. Svennilson is deemed to hold the option for the economic benefit of the Funds. The reporting persons may be deemed indirect beneficial owners of the option. The reporting persons disclaim beneficial ownership of the option except to the extent of their pecuniary interest therein.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
COLUMN GROUP II, LP
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X

Column Group II GP, LP
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X
General Partner
PONOI CAPITAL, LP
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X

Ponoi Management, LLC
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X
General Partner
Ponoi Capital II, LP
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X

Ponoi II Management, LLC
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X
General Partner
Kutzkey Tim
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X
Managing Partner
GOEDDEL DAVID V
1700 OWENS STREET
SUITE 500
SAN FRANCISCO, CA 94158
X
Managing Partner
Signatures
/s/ Jennifer J. Carlson, Attorney-in-fact6/22/2020
**Signature of Reporting PersonDate
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more RAPT Therapeutics Charts.
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more RAPT Therapeutics Charts.